Sign Up

AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'

AstraZeneca Plc (NASDAQ:AZN) reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion. 

The company’s adjusted EPADS reached $1.04, beating the consensus of $1.03. The adjusted EPS was $2.08 (1 ADR = 2 Common Shares).

AstraZeneca’s top business, oncology, increased 19% (up 22% on constant currency) to $5.57 billion.

Tagrisso sales were up 14% to $1.67 billion (17% at CER), Calquence sales increased 24% (25% at CER) to $8.13 million, and Enhertu revenue was up 50% (55% at CER) to $510 million.

Cardiovascular, Renal, and Metabolism (CVRM) sales increased 18% (up 20 at CER)% to $3.16 billion.

Farxiga sales were up 25% (27% at CER) to $1.94 billion, and Lokelma sales increased 40% (42% at CER) to $143 million.

R&I Respiratory & Immunology sales increased 26% (29% CER) to $1.96 billion.

Rare Disease drug sales increased by 9% (+11% at CER) to $2.15 billion.

Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue ...